Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Due to an intra-group subsidiary merger (Altos Biologics absorbing Alteogen Healthcare), Alteogen will acquire 859,018 new shares (approx. KRW 31.17B) of Altos Biologics, increasing its stake to 63.46% with no additional cash outlay.
📊 [Key Disclosure Details & Financial Highlights]
- Target Corporation: Altos Biologics Corp. (CEO: Hee Jeong Ji, Main Business: Pharmaceutical R&D, Subsidiary)
- Acquisition Details:
- Number of Shares: 859,018 shares (New shares acquisition)
- Acquisition Amount: KRW 31,165,173,040 (21.08% of equity / 12.17% of consolidated total assets)
- Total Shares and Ownership Ratio After Acquisition: 5,859,018 shares (63.46%)
- Purpose: Enhancing operational efficiency through organizational integration via intra-group subsidiary merger
- Scheduled Acquisition Date: 2024-12-24
- Board Resolution Date: 2024-11-07
- Key Notes:
- Share acquisition resulting from intra-group merger (Surviving: Altos Biologics, Dissolved: Alteogen Healthcare) involving no additional cash investment, only accounting consolidation of investment amounts
- Acquisition price based on the issuance price of 3rd-party capital increase within the past 6 months
- Financial Summary of Target Corporation (Altos Biologics Corp., Unit: KRW Millions):
- Current Year: Total Assets 63,427 / Total Liabilities 5,562 / Total Equity 57,864 / Capital Stock 3,472 / Revenue – / Net Loss -3,339
- Previous Year: Total Assets 61,862 / Total Liabilities 4,239 / Total Equity 57,622 / Capital Stock 3,445 / Revenue – / Net Loss -2,713
- Year Before Previous: Total Assets 62,206 / Total Liabilities 3,085 / Total Equity 59,121 / Capital Stock 3,445 / Revenue – / Net Loss -2,579
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Completion of Subsidiary Merger and Share Acquisition
This disclosure outlines the acquisition of new shares resulting from the reorganization and merger between subsidiaries. Verifying whether the merger and share acquisition procedures are finalized smoothly by the target date of December 24, 2024, without additional cash outflow, is important to track restructuring progress. Further status updates can be confirmed through future disclosures and upcoming periodic business reports on DART.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For inquiries regarding regulatory compliance or copyright requests, please contact ksb220805@gmail.com.
